Samalizumab

• CAT Number: I042197
• CAS Number: 1073059-33-2
• Purity: ≥95%

Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research[1].
Samalizumab is rationally engineered with an Ig G2/G4 constant region to minimize effector function and preserve immune cell subsets. Samalizumab is a first-in-class, recombinant humanized anti-CD200 mAb, engineered to ablate effector function, that specifically binds to the immune checkpoint CD200, blocks receptor engagement and signaling and antagonizes CD200-driven immune suppression, thereby mount an anti-tumor immune response[1].

Reference

[1]. Daruka Mahadevan, et al. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. J Immunother Cancer. 2019 Aug 23;7(1):227.
 [Content Brief]